| Similar Articles |
|---|
 |
The Motley Fool
April 23, 2007
Brian Lawler |
Trimeris Isn't Tumbling Trimeris announces first-quarter sales numbers for its HIV drug Fuzeon. Shares of the company were up 25% last week after it reported stronger-than-expected sales of the fusion inhibitor.   |
The Motley Fool
April 23, 2004
Charly Travers |
A Difficult Drug Launch Investors expected a lot from Fuzeon, Trimeris' HIV drug therapy. However, anticipated sales for the biotechnology company didn't materialize. |
The Motley Fool
November 30, 2007
Brian Lawler |
Not What Trimeris Needs Small biopharma Trimeris revealed that it and partner Roche were being sued for patent infringement by Novartis over Trimeris' only marketed compound, Fuzeon. |
The Motley Fool
July 19, 2007
Brian Orelli |
Trimeris Reaches a Plateau Drug developer Trimeris needs to push another drug out of its pipeline because sales of its only drug, Fuzeon, appear to be hitting the wall. Investors, take note. |
The Motley Fool
November 16, 2007
Brian Lawler |
Trimeris Gets a Cleanup Hitter Tiny drug developer Trimeris announces that it has finally found a permanent CEO to help get itself in order following the resignation of its former leader a year ago. |
The Motley Fool
March 19, 2007
Brian Lawler |
Trimeris Gets Trimmed Shares of the drug developer are down after a management shakeup. With shares trading near their 52-week lows amid all the pessimism, now is a good time for less-risk adverse investors to buy in. |
The Motley Fool
August 15, 2007
Brian Lawler |
Call for Change at Trimeris A shareholder group criticizes tiny Trimeris about its spending on research. In an SEC filing, HealthCor, which owns 15% of the outstanding shares, called for the pharmaceutical company to cut back on its research and development expenses and to explore selling the company. |
The Motley Fool
July 19, 2010
Brian Orelli |
Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so. |
The Motley Fool
July 13, 2004
Charly Travers |
With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market. |
The Motley Fool
June 26, 2008
Brian Lawler |
Ardea Takes the More Exciting Route Ardea Bioscicences announces phase 2a data for its lead anti-HIV drug that is good enough to encourage further testing. |
The Motley Fool
November 20, 2006
Karl Thiel |
Trimeris Begs for a Buyout The pharmaceutical's reorganization plan practically posts a "for sale" sign. So will Roche -- or someone else -- bite? Investors, take note. |
The Motley Fool
May 2, 2007
Brian Lawler |
Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note. |
American Journal of Nursing
March 2010
David E. Vance |
Aging with HIV: Clinical Considerations for an Emerging Population Since the advent of highly active antiretroviral therapy, HIV infection has become a chronic, albeit life-threatening, condition that can be managed; therefore, more and more people are growing older with HIV. |
The Motley Fool
January 7, 2004
Alyce Lomax |
Try Again, Trimeris Headline skimmers, beware. When a company plays "hide and seek," and the object that's hiding is a piece of bad news, it's no laughing matter to investors. Trimeris got busted Monday following market close after it issued what was considered a rather deceptive press release. |
The Motley Fool
June 30, 2011
Brian Orelli |
2 Backdoor Biotech IPOs to Watch Just don't buy yet. |
BusinessWeek
November 24, 2003
John Carey |
Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells. |
American Journal of Nursing
March 2010
Bradley-Springer et al. |
Every Nurse Is an HIV Nurse The evolution of HIV infection into a chronic disease has implications across all clinical care settings. Every nurse should be knowledgeable about the disease in order to provide high-quality care to people with or at risk for HIV. |
Managed Care
May 2005 |
Antiretroviral Coverage Lacking in 30 Percent of ADAPs There are 57 AIDS Drug Assistance Programs (ADAPs), yet nearly 30% do not include coverage of all FDA-approved antiretroviral therapies on their formularies, and South Dakota does not provide any protease inhibitor coverage at all, according to an annual report. |
